DK4114465T5 - Anti-ifnar1-doseringsplan til subkutan injektion - Google Patents

Anti-ifnar1-doseringsplan til subkutan injektion Download PDF

Info

Publication number
DK4114465T5
DK4114465T5 DK22724683.2T DK22724683T DK4114465T5 DK 4114465 T5 DK4114465 T5 DK 4114465T5 DK 22724683 T DK22724683 T DK 22724683T DK 4114465 T5 DK4114465 T5 DK 4114465T5
Authority
DK
Denmark
Prior art keywords
ifnar1
subcutaneous injection
dosage schedule
schedule
dosage
Prior art date
Application number
DK22724683.2T
Other languages
English (en)
Other versions
DK4114465T3 (da
Inventor
Catharina Lindholm
Joachim Almquist
Tomas Rouse
Yen Lin Chia
Rajendra Tummala
Lorin Roskos
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81750490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4114465(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK4114465T3 publication Critical patent/DK4114465T3/da
Publication of DK4114465T5 publication Critical patent/DK4114465T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Devices For Medical Bathing And Washing (AREA)
DK22724683.2T 2021-04-23 2022-04-21 Anti-ifnar1-doseringsplan til subkutan injektion DK4114465T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US202163272851P 2021-10-28 2021-10-28
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Publications (2)

Publication Number Publication Date
DK4114465T3 DK4114465T3 (da) 2023-10-30
DK4114465T5 true DK4114465T5 (da) 2024-07-22

Family

ID=81750490

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22724683.2T DK4114465T5 (da) 2021-04-23 2022-04-21 Anti-ifnar1-doseringsplan til subkutan injektion

Country Status (25)

Country Link
US (4) US20220340669A1 (da)
EP (2) EP4114465B1 (da)
JP (2) JP7484027B2 (da)
KR (2) KR20250092298A (da)
CN (2) CN120392997A (da)
AU (2) AU2022260531B2 (da)
BR (1) BR112023021761A2 (da)
CA (1) CA3216387A1 (da)
CL (1) CL2023003114A1 (da)
CO (1) CO2023015498A2 (da)
DK (1) DK4114465T5 (da)
ES (1) ES2963757T3 (da)
FI (1) FI4114465T3 (da)
HR (1) HRP20231255T1 (da)
HU (1) HUE063562T2 (da)
IL (1) IL307748A (da)
LT (1) LT4114465T (da)
MX (1) MX2023012465A (da)
PL (1) PL4114465T3 (da)
PT (1) PT4114465T (da)
RS (1) RS64821B1 (da)
SI (1) SI4114465T1 (da)
SM (1) SMT202300382T1 (da)
TW (1) TW202317182A (da)
WO (1) WO2022223714A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
WO2022106460A2 (en) * 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CA3216395A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法
AU2024277546A1 (en) 2023-05-19 2026-01-15 Astrazeneca Ab Treatment of lupus
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
KR101225299B1 (ko) 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN101678116A (zh) 2006-05-11 2010-03-24 根特大学 通过唾液酸粘附素靶向巨噬细胞
EP2712930A3 (en) 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
EP2666873B1 (en) 2007-07-12 2016-03-09 The Brigham and Women's Hospital, Inc. Compositions and methods for diagnosing and assessing inflammatory myopathies
NZ585064A (en) 2007-11-05 2012-08-31 Medimmune Llc Methods of treating scleroderma
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
US20110287022A1 (en) 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
WO2010019952A2 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
KR102320059B1 (ko) 2012-06-13 2021-11-01 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
JP7013632B2 (ja) * 2018-09-18 2022-02-01 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
SG11202108679PA (en) * 2019-02-15 2021-09-29 Astrazeneca Ab Type i interferon-mediated disorders
EP4494712A3 (en) 2019-11-11 2025-03-26 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
EP4157873A2 (en) 2020-05-29 2023-04-05 Astrazeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
WO2022106460A2 (en) * 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CA3216395A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Also Published As

Publication number Publication date
US20230365698A1 (en) 2023-11-16
US20220340669A1 (en) 2022-10-27
CA3216387A1 (en) 2022-10-27
TW202317182A (zh) 2023-05-01
EP4114465A1 (en) 2023-01-11
LT4114465T (lt) 2023-11-10
RS64821B1 (sr) 2023-12-29
IL307748A (en) 2023-12-01
KR20230166134A (ko) 2023-12-06
US12060429B2 (en) 2024-08-13
AU2022260531A1 (en) 2023-11-30
US20240360231A1 (en) 2024-10-31
DK4114465T3 (da) 2023-10-30
FI4114465T3 (fi) 2023-10-31
KR20250092298A (ko) 2025-06-23
JP7484027B2 (ja) 2024-05-15
BR112023021761A2 (pt) 2023-12-26
SMT202300382T1 (it) 2024-01-10
CO2023015498A2 (es) 2023-11-30
AU2024201743A1 (en) 2024-04-04
HUE063562T2 (hu) 2024-01-28
AU2022260531A9 (en) 2023-12-07
CN120514844A (zh) 2025-08-22
AU2022260531B2 (en) 2024-03-07
CL2023003114A1 (es) 2024-04-19
SI4114465T1 (sl) 2023-11-30
PT4114465T (pt) 2023-11-03
ES2963757T3 (es) 2024-04-01
JP2024511227A (ja) 2024-03-12
JP7805393B2 (ja) 2026-01-23
WO2022223714A1 (en) 2022-10-27
JP2024102205A (ja) 2024-07-30
EP4306541A2 (en) 2024-01-17
HRP20231255T1 (hr) 2024-02-02
PL4114465T3 (pl) 2024-04-08
EP4306541A3 (en) 2024-03-27
EP4114465B1 (en) 2023-08-30
CN120392997A (zh) 2025-08-01
US20240400699A1 (en) 2024-12-05
MX2023012465A (es) 2024-04-04

Similar Documents

Publication Publication Date Title
DK4114465T5 (da) Anti-ifnar1-doseringsplan til subkutan injektion
DK3801694T3 (da) Injektor til auto-indføring
JP1715470S (ja) 医療用注入器
JP1715472S (ja) 医療用注入器
EP3750579A4 (en) INJECTOR
EP3826702A4 (en) INJECTOR
EP4031214C0 (en) INJECTION SYSTEMS
EP4483926A4 (en) AUTOMATIC INJECTION PEN
GB2622328B (en) Injection needle
EP4392717A4 (en) MICROMIX FUEL INJECTION AIR NOZZLE
EP4218858A4 (en) Injector
EP3782676C0 (en) BALLOON TYPE LIQUID MEDICATION INJECTOR
EP4410331A4 (en) SYRINGE
IL289260A (en) Injection device
IL282842A (en) Pharmaceutical formulations for subcutaneous administration
EP4649975A4 (en) QUANTITATIVE INJECTION SYRINGE
EP3904039A4 (en) INJECTOR
EP3813907C0 (en) NEEDLE-FREE INJECTION SYSTEM
EP4275717A4 (en) Injector
IL314270A (en) Autoinjector
EP4029505C0 (en) INJECTION CONTAINING P-BORONOPHENYLALANINE
EP3986507C0 (en) INJECTION SYSTEM
EP3590395C0 (en) INJECTOR NEEDLE
DK3813725T3 (da) Anordning til injicering i fjerkræ
HUE051787T2 (hu) Injektor fröccsöntéshez